GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » Cyclically Adjusted Book per Share

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Cyclically Adjusted Book per Share : $2.12 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Adaptimmune Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $0.174. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.12 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-05-11), Adaptimmune Therapeutics's current stock price is $1.12. Adaptimmune Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $2.12. Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio of today is 0.53.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Adaptimmune Therapeutics was 0.83. The lowest was 0.33. And the median was 0.56.


Adaptimmune Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Adaptimmune Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics Cyclically Adjusted Book per Share Chart

Adaptimmune Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.12

Adaptimmune Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 2.12

Competitive Comparison of Adaptimmune Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio falls into.



Adaptimmune Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adaptimmune Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.174/130.0000*130.0000
=0.174

Current CPI (Dec. 2023) = 130.0000.

Adaptimmune Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201306 -0.005 98.000 -0.007
201312 0.000 99.200 0.000
201406 0.006 99.800 0.008
201409 0.000 100.000 0.000
201412 1.333 99.900 1.735
201506 3.659 100.100 4.752
201509 3.541 100.200 4.594
201512 0.000 100.400 0.000
201603 3.093 100.400 4.005
201606 2.783 101.000 3.582
201609 2.543 101.500 3.257
201612 2.347 102.200 2.985
201703 2.409 102.700 3.049
201706 2.454 103.500 3.082
201709 2.444 104.300 3.046
201712 2.167 105.000 2.683
201803 2.032 105.100 2.513
201806 1.749 105.900 2.147
201809 2.642 106.600 3.222
201812 2.361 107.100 2.866
201903 2.098 107.000 2.549
201906 1.779 107.900 2.143
201909 1.404 108.400 1.684
201912 1.176 108.500 1.409
202003 1.430 108.600 1.712
202006 2.636 108.800 3.150
202009 2.431 109.200 2.894
202012 2.204 109.400 2.619
202103 1.989 109.700 2.357
202106 1.781 111.400 2.078
202109 1.543 112.400 1.785
202112 1.318 114.700 1.494
202203 1.040 116.500 1.161
202206 0.872 120.500 0.941
202209 0.692 122.300 0.736
202212 0.498 125.300 0.517
202303 0.506 126.800 0.519
202306 0.562 129.400 0.565
202309 0.388 130.100 0.388
202312 0.174 130.000 0.174

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Adaptimmune Therapeutics  (NAS:ADAP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Adaptimmune Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.12/2.12
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Adaptimmune Therapeutics was 0.83. The lowest was 0.33. And the median was 0.56.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Adaptimmune Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description

Traded in Other Exchanges
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Executives
Elliot Norry officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger officer: Chief Patient Supply Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe officer: Chief Financial Officer 440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Kristen Hege director 500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen director 2525 28TH STREET, SUITE 200, BOULDER CO 80301
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Gavin Wood officer: Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer officer: Chief Scientific Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble director, officer: Chief Executive Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Headlines

From GuruFocus